Sony June 19, 2012 – Tokyo , Japan (Techreleased) –Corporation ( “Sony”) today announced the development of ‘Spectral’ cell analyzer, its second ‘flow cytometer’ cell analysis instrument(*) for the optical analysis of cells. Sony will also exhibit its prototype at ISAC (the International Society for Advancement of Cytometry) in Leipzig, Germany, from June 23 – 27.
This high-end cell analyzer adopts a newly-developed ‘spectral’ cytometry method to detect full spectrum fluorescent emissions, making highly complex analysis a simple task. By introducing this method, Sony aims to propose a novel method of cell analysis to researchers in advanced research fields such as immunology, oncology, and regenerative medicine.
‘Flow cytometer’ cell analysis instrument
There are two types of flow cytometers: ‘cell analyzers’ exclusively for analyzing cells, and ‘cell sorters’ for both analyzing and sorting cells. Both types of flow cytometers are used by university laboratories, research institutes, and pharmaceutical companies in studies involving immunology and oncology, as well as research for regenerative medicine and stem cells, such as iPS (induced pluripotent stem) and ES (embryonic stem) cells. Flow cytometers are expected to further proliferate as research in these and other clinical areas continues to expand.
The main features of Sony’s cell analyzer
In order to detect fluorescence, conventional cell analyzers use optical filters to divide the fluorophores based on the fluorescence wavelength range (channel), which enables isolated measurement of only an intensity of fluorescence. Therefore, in order to detect multiple colors a corresponding number of optical filters, detectors, and fluorophores are required.
However, by this method, multiple fluorophores can overlap in a single channel (Figure 1), leading to additional spectral compensation or correction work. Consequently, the increase in the number of fluorescent reagents has posed various problems in analysis accuracy, reproducibility, and workefficiency.
Sony aims to achieve mid- to long-term growth in its medical business, and will strive to expand and strengthen its range of flow cytometers to deliver high-quality, innovative products.